Guggenheim initiated coverage of Myriad Genetics with a Buy rating and $23 price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics initiated with bullish view at Wolfe Research, here’s why
- Myriad Genetics initiated with bullish view at Wolfe Research
- Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
- Myriad Genetics, Personalis enter pact for biomarker discovery platform
- Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers